Clinical Trials Logo
  1. Home
  2. Non-melanomatous Skin Cancer
  3. NCT00021294

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

Non-melanomatous Skin Cancer Clinical Trial

Official title:
Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on the Forearms

Clinical Trial Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Eflornithine with or without triamcinolone may be effective in preventing nonmelanoma skin cancer.

PURPOSE: Randomized phase II trial to compare the effectiveness of eflornithine with or without triamcinolone in preventing nonmelanoma skin cancer in patients who have actinic keratosis.

Clinical Trial Description

OBJECTIVES: I. Compare the safety and efficacy of eflornithine (DFMO) vs placebo as chemoprevention of non-melanoma skin cancer in patients with moderate to heavy actinic keratosis (AK). II. Determine whether this drug reverses AK in these patients. III. Determine whether triamcinolone reduces DFMO-induced skin irritation in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to 1 of 4 treatment arms. Arm I: Patients receive eflornithine (DFMO) topically and triamcinolone topically to forearms once daily. Arm II: Patients receive DFMO and placebo topically as in arm I. Arm III: Patients receive placebo and triamcinolone topically as in arm I. Arm IV: Patients receive 2 placebos topically as in arm I. Treatment continues for 6 months in the absence of unacceptable toxicity. Patients are followed at 2 weeks.

PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study within 1 year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00021294
Study type Interventional
Source University of Arizona
Contact
Status Completed
Phase Phase 2
Start date May 2001
Completion date June 2002
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00423397 - Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer Phase 1/Phase 2
Completed NCT00103246 - Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides Phase 1
Active, not recruiting NCT00391300 - Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions Phase 1
Completed NCT00066872 - Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Phase 3
Completed NCT00002963 - Photodynamic Therapy in Treating Patients With Skin Cancer Phase 2
Completed NCT00003611 - Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation N/A
Terminated NCT00663910 - Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer Phase 0
Recruiting NCT00295906 - Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control N/A
Completed NCT00025012 - Isotretinoin in Preventing Skin Cancer N/A
Completed NCT00021125 - Radiation Therapy in Treating Patients With Head and Neck Cancer Phase 3
Completed NCT00601640 - Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin Phase 2
Completed NCT00079300 - Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer Phase 1
Completed NCT00017485 - Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer Phase 1
Recruiting NCT00747903 - Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer Phase 2
Terminated NCT00899132 - Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer N/A
Completed NCT00099112 - Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type II N/A
Completed NCT00644384 - Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer N/A
Completed NCT00023621 - Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome Phase 2
Completed NCT00002975 - Photodynamic Therapy in Treating Patients With Skin Cancer Phase 2
Completed NCT00295958 - LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery Phase 2